Thursday, June 14, 2018 12:26:45 PM
Shares of the pharmaceutical giant, Mylan NV (NASDAQ:MYL), are falling by nearly 5.0 percent to $39.70 a share. The sharp decline in the stock comes after the FDA said that it found minor deficiencies in Mylan's generic version of Advair. Today, the stock is fighting to stay above its important 50 and 200-day moving averages. A close below these key support levels will signal further downside in the stock price. Either way, should the stock decline further from current levels the next major support area would be around the $35.00 area. This is where the stock broke out on early May 2018 and should be defended by the institutional crowd if retested.
Nicholas Santiago
InTheMoneyStocks
Recent VTRS News
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
